Changing the Rules of TB-Drug Discovery

James Harrison, Jonathan A. G. Cox

Research output: Contribution to journalArticlepeer-review


The discovery of new drugs with novel targets is paramount to the continued success of tuberculosis (TB) treatment due to the increasing prevalence of antibiotic resistant infections in the TB population. Mycobacterium tuberculosis (Mtb) fumarate hydratase (fumarase) is a highly conserved essential protein that shares an active site with human fumarase, making active site inhibition equally cytotoxic for both bacteria and humans. The recent discovery of a set of new Mtb inhibitory compounds that target Mtb-fumarase by binding to a nonconserved allosteric site is a major advancement, providing further evidence to dispel the antibiotic discovery dogma that conserved proteins do not make good antibiotic targets.
Original languageEnglish
Pages (from-to)10583-10585
Number of pages3
JournalJournal of Medicinal Chemistry
Issue number23
Early online date30 Oct 2019
Publication statusPublished - 12 Dec 2019

Bibliographical note

This document is the Accepted Manuscript version of a Published Work that appeared in final form in J. Med. Chem., copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see


Dive into the research topics of 'Changing the Rules of TB-Drug Discovery'. Together they form a unique fingerprint.

Cite this